Showing 481-490 of 1554 results for "".
The State of Optometry’s Financial Health
https://modernod.com/topics/business/the-state-of-optometrys-financial-health/38792/Five takeaways from the largest income survey conducted in optometry.Blessings and Opportunities
https://modernod.com/topics/business/blessings-and-opportunities/38667/ICSC: A History and Preview
https://modernod.com/topics/contact-lenses/icsc-a-history-and-preview/37913/It’s Time to Knock Glaucoma Down a Few Pegs
https://modernod.com/topics/glaucoma/its-time-to-knock-glaucoma-down-a-few-pegs/38917/Ready to Enter the World of Aesthetics?
https://modernod.com/topics/ocular-surface/ready-to-enter-the-world-of-aesthetics/38802/Working up to optimal care will give you the best chance of success.OSD Is Coming! OSD Is Coming!
https://modernod.com/mod-issues/2022-july-aug/osd-is-coming-osd-is-coming/38458/Today’s Perspectives on Myopia Management
https://modernod.com/topics/myopia/todays-perspectives-on-myopia-management/38830/Important insights from those in the trenches treating the condition."One World—Scleralize It!"
https://modernod.com/topics/contact-lenses/one-world-scleralize-it/38420/Highlights from the International Congress of Scleral Contacts meeting.Glaukos Submits NDA for Epi-On CLX Candidate
https://modernod.com/podcasts/eyewire-news-the-podcast/glaukos-submits-nda-for-epi-on-clx-candidate/37066/Glaukos submits a new drug application to the FDA for its next-generation cross-linking therapy; Regeneron releases phase 3 results for Eylea HD for RVO; and Regeneron acquires a clinical stage biotech making ocular delivery technology for retinal disorders. Learn more about your ad choices. Visit mPractice Efficiency and Innovation
https://modernod.com/programs/empower/empower-practice-efficiency-and-innovation/48683/Part five of a five-part business/specialty care optometric series.